疑似早期卵巢癌的前哨淋巴结技术:腹腔镜技术
该视频展示在疑似早期卵巢癌患者中腹腔镜下实施前哨淋巴结技术的可行性,操作在SENTOV临床试验(NCT03452982)框架内进行,注射点位于骨盆漏斗韧带和卵巢韧带残端,联合使用锝-99m纳米胶体和吲哚菁绿示踪,2017至2019年间该技术应用于30例患者(其中13例腹腔镜),结论认为腹腔镜前哨淋巴结技术在卵巢癌中似乎可行。
要点
- 腹腔镜前哨淋巴结技术在疑似早期卵巢癌中似乎可行,操作在SENTOV临床试验框架内进行。
- 注射点位于骨盆漏斗韧带和卵巢韧带残端,联合使用锝-99m纳米胶体和吲哚菁绿示踪。
- 2017至2019年间该技术应用于30例患者,其中13例为腹腔镜手术。
核心结论
- 腹腔镜前哨淋巴结技术在卵巢癌中似乎可行(seems to achievable)。
研究设计与样本
- 视频展示在疑似早期卵巢癌患者中腹腔镜下实施前哨淋巴结技术,操作在SENTOV临床试验(NCT03452982)框架内进行。
- 2017至2019年间该技术应用于30例患者,其中13例为腹腔镜手术。
主要发现
- 注射点位于骨盆漏斗韧带和卵巢韧带残端。
- 每个注射点使用27G针注射200微升含37 MBq锝-99m纳米胶体的生理盐水,随后注射0.5毫升吲哚菁绿。
- 注射后即刻及注射后15分钟和30分钟,在伽马探头声信号和近红外相机引导下检查术野。
- 任何放射性计数高达背景10倍和/或染有吲哚菁绿的淋巴结被视为前哨淋巴结并单独切除。
- 前哨淋巴结操作完成后进行系统性手术分期。
关键数值与推荐
- 截至本文,疑似早期卵巢癌诊断后推荐行淋巴结切除术作为手术分期的一部分。
- 可考虑微创手术用于再分期。
- 盆腔和腹主动脉旁淋巴结切除术后,高达14%的患者因淋巴结阳性而分期升高。
- 低级别肿瘤的淋巴结受累率较低。
- 近期一项先导研究报告前哨淋巴结技术可行。
临床怎么用
- 作者提出联合使用锝-99m纳米胶体和吲哚菁绿两种方法,因吲哚菁绿分子小、不被淋巴结瓣膜系统截留而持续迁移,锝-99m纳米胶体因分子大小被截留于淋巴结瓣膜系统而不持续迁移。
- 作者指出需要详尽直接观察染料路径以避免误导检测真正的前哨淋巴结。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To demonstrate the feasibility of laparoscopic sentinel lymph node technique in presumed early-stage ovarian cancer. DESIGN: Video illustrating the laparoscopic performance of the sentinel lymph node technique in ovarian cancer. SETTING: The Oncologic Gynecology Department at the University Hospital La Fe. PATIENTS: Candidates for the technique presented an apparent early stage ovarian cancer. The technique was performed in the context of a clinical trial called SENTOV (NCT03452982). INTERVENTIONS: To date, lymphadenectomy is recommended after the diagnosis of apparent early-stage ovarian cancer as part of the surgical staging. Minimally invasive surgery can be considered for the purpose of restaging [1]. Up to 14% of the patients are upstaged because of positive lymph nodes after pelvic and para-aortic lymphadenectomy [2]. Regarding low-grade tumors, a lower rate of lymph node involvement has been reported [3]. Sentinel lymph node technique has been reported to be feasible in a recent pilot study [4]. Two clinical trials (Sentinel Lymph Node in Early Ovarian Cancer and Sentine Lymph Node in Early Ovarian Cancer) are currently ongoing to clarify the use of sentinel lymph node technique in early ovarian cancer. The injection points were at the infundibulopelvic and ovarian ligament stumps. Two hundred microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) was injected subperitoneally. We used a 27 G needle at each injection point. Immediately after injection and also at 15 and 30 minutes after injection, the operative field was checked guided by the acoustic signal of the gamma probe and the near-infrared camera. We performed a minimum dissection looking for the sentinel lymph node or nodes in the pelvic and para-aortic region. Any lymph node with a remarkable radioactivity count as high as 10 times the background and/or dyed with ICG was considered a sentinel lymph node and was harvested separately. A systematic surgical staging was performed after the sentinel lymph node procedure was completed. Because of its small size, the ICG molecule is not caught in the lymph node valve system and keeps migrating when performing lymphography. An exhaustive direct view of the dye path is required to avoid misleading detection of the real sentinel lymph node. This theoretical problem is resolved by the use of the 99mTC-nanocolloid. This tracer gets trapped into the lymph node valve system because of its molecular size and does not keep migrating as does ICG. As such, a combination of both methods is proposed. CONCLUSION: Laparoscopic performance of sentinel lymph node technique in ovarian cancer seems to achievable. Between 2017 and 2019, this procedure was performed in 30 patients (13 laparoscopic), in the context of our pilot experience [4] and the Sentinel Lymph Node in Early Ovarian Cancer clinical trial (NCT03452982).
引用
- Lago V, Bello P, Matute L, et al. Sentinel Lymph Node Technique in Apparent Early Ovarian Cancer: Laparoscopic Technique. J Minim Invasive Gynecol. 2019. PMID: 31628986. doi:10.1016/j.jmig.2019.09.790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。